LEXX News & Events

Lexaria Bioscience announces the beginning of its 2026 research and development program designed to broaden pharmaceutical, intellectual property, and business development opportunities through new and improved formulations. Information on 3 new studies from the 2026 R&D Program which are representative of the Company's primary areas of focus during at least the first three quarters of the calendar year, is being released today, however these studies do not necessarily encompass the entire 2026 R&D Program. "Our 2026 R&D Program might be the most focused on practical results that the Company has ever conducted," stated Richard Christopher, CEO of Lexaria. "These studies are specifically concentrated on increasing the likelihood of pharma industry partnerships and the creation of new intellectual property," continued Mr. Christopher. "Some of this work must intentionally remain obscure at this time since, if successful, it could likely lead to expanded new IP and patent development."

Lexaria Bioscience announced final results from Human Pilot Study #5, which compared oral DehydraTECH-liraglutide capsules to injected Saxenda branded liraglutide. The primary results from this Study were issued on June 11, 2025, at which time Lexaria reported a 22.7% reduction in adverse events with DHT-LIR as compared to the SAX-LIR, with a particular emphasis on a 67% reduction in nausea and a 31% reduction in overall gastrointestinal AEs. The differences in measurements of blood glucose, insulin and body weight across most time points were not statistically significantly different, with remarkable similarity in many areas and slight differences in others. Weight loss was experienced by 9 out of 10 people in each Study arm and slightly higher in the Saxenda Study arm; though weight loss was not a primary goal of this Study with the very short treatment period of only 1 week with each treatment. Evaluating the safety and tolerability of the oral DHT-LIR capsules relative to injected SAX-LIR was the primary endpoint of this Study. This objective was met with clear signs of improved safety and tolerability performance by the DHT-LIR. Since mid-2025, Lexaria and its third-party bioanalytical service providers have invested considerable time and expertise in attempting to determine the precise pharmacokinetic blood liraglutide quantitation and profiling results from the Study. This included the use of two different manufactured brands of commercially available ELISA test kits. Throughout the course of this bioanalytical work, challenges were encountered with background signal noise detection, which complicated our ability to accurately capture blood liraglutide measurements in both the SAX-LIR and DHT-LIR study samples. The background signal noise is believed to be attributable to the fact that liraglutide and other peptide drugs are commonly known to bind with, and have poor separation from, albumin, a naturally occurring protein present in human blood plasma. In light of this issue, the PK testing from the Study was limited to exploratory visualization of the raw ELISA signals which, nonetheless, over time demonstrated broadly similar temporal patterns between the DHT-LIR and the SAX-LIR. The visualization of the similar signal patterns of the two treatments is consistent with the instances of functional comparability otherwise demonstrated in the Study, pursuant to Lexaria's regulatory development pathway objectives. Lexaria considers this to be particularly noteworthy given the fact that the DHT-LIR dose quantity studied was conservatively low for this initial human investigation, relative to that of the SAX-LIR, with room for possibly increasing the dose if necessary in potential future studies. The two most important strategic objectives of this Study were: To discover whether the DehydraTECH processing of liraglutide would work sufficiently enough to potentially allow for an oral version of the drug to be compared to the current injection-only delivery method; and To demonstrate that oral DHT-LIR could produce comparable functional results to the injected version, allowing for an expedited FDA regulatory development pathway known as a 505(b)(2) new drug application that is available when an alternate version of a drug retains certain similar performance characteristics as an earlier-approved version of that same drug. In both these respects, the results from this Study have shown tremendous promise while also evidencing tolerability advantages from a user appeal perspective.

The Company now has a total of 60 valid patents granted around most of the major potential markets around the world. The company said, "Lexaria's previous update on patents was issued on October 9, 2025. Since then, we have diligently pursued legal recognition of our innovations leading to intellectual property and are delighted to have enjoyed considerable success through the receipt of 6 new granted patents. In our patent Family #20, Compositions and Methods for Sublingual Delivery of Nicotine, where we have existing granted patents in the US, Canada, and Japan, we have received our first patent in Australia. We have received our first European Union patent in patent Family #21, Compositions and Methods for Treating Hypertension, where we already have 3 US granted patents. Europe is considered the 2nd-largest hypertension market in the world and thus receiving European patent recognition is an important milestone. In our patent Family #24, Compositions and Methods for Treating Epilepsy, we have received 2 new Australian patents and 1 new European Union patent. Our intellectual property in this important Family is now quite robust with a total of 6 US patents; 4 Australian patents; and 1 European Union patent. Finally, in our patent Family #27, Compositions and Methods for Treating Diabetes, we have received 1 new US patent. We now have 2 US patents in this Family which we consider to be quite important given our recent successes in the GLP-1 sector."

Lexaria Bioscience provided an Annual Letter from its CEO Richard Christopher as a strategic update to all stakeholders, which read in part, "I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position. I'm pleased to report that, in 2025, Lexaria made significant progress in further evidencing the potential to advance oral based drug delivery within the GLP-1 sector with the use of its proprietary DehydraTECH technology. A number of human and animal studies were conducted and concluded in 2025 which produced extremely encouraging safety and tolerability, pharmacokinetic, weight loss, blood glucose, insulin, biodistribution, and blood pressure results...Even before our 2025 R&D program came to an end, we had already begun scoping out work plans for 2026 to build upon key lessons learned to-date. Although we are not ready today to provide detailed plans of that work, we certainly can provide some basic guidance. Our #1 priority remains GLP-1, and specifically, our relationship with our MTA partner. Our 2025 Human Study #4 produced extremely important information that greatly advanced our DHT-GLP-1 program. Indeed, Human Study #4 provided us with vital clues that we intend to utilize to formulate potentially new and improved oral GLP-1 products, as measured both by reduced AE's and impressive performance. Therefore, we have already started designing our next DHT-GLP-1 human study to leverage advanced, next-generation DHT oral formulations that no other company in the world possesses. Once we have finalized this study design, it will be announced and vigorously pursued. As currently envisioned, we would expect to complete this study during calendar 2026, and we can fully fund it using existing Company resources. We are also considering a new animal study under design to explore additional new and improved DHT-GLP-1 formulations, including leading developmental GLP-1 peptide agonists not previously tested together with DHT. Lexaria's DHT technology is a dynamic platform that allows us to build layers of specialized and varied ingredients on top of standard patented processes; this compatibility grants us numerous choices when optimizing for different drugs, and that optimization process for DHT-GLP-1 is by no means complete! While design work is still ongoing, we expect to complete this study during calendar 2026 as well utilizing existing Company resources. Also, as noted above, we plan to also take additional steps in 2026 to investigate whether DHT-processed liraglutide might offer relatively rapid access to the marketplace via the expedited 505(b)(2) development pathway. This may involve select R&D activities, fully funded using existing Company resources, and the exploration of prospective strategic corporate partnering interest and opportunities to support this program. Newer shareholders might not fully realize the adaptability that DHT offers, and I believe it is important to convey that our DHT-GLP-1 formulation explorations are not complete and may yet yield even more powerful results than have been obtained to date. As such, part of our ongoing work is to continually explore additional formulations in search of higher performance. The animal and human studies under consideration will be designed to do exactly this. We are also exploring additional R&D in areas outside of GLP-1. We've conducted work in many sectors since our original discovery of DHT, and we have intriguing commercial opportunities that remain untapped. Once design work has been more fully completed, we will announce those studies that we decide to pursue."